Malignancy Rate in Thyroid Nodules with Atypia or Follicular Lesion of Undetermined Significance

Hamdan Ahmed Pasha1, Rahim Dhanani1, Ainulakbar Mughal1, Kaleem S. Ahmed1, Anwar Suhail1

1 Department of Surgery, Section of Otolaryngology/Head and Neck Surgery, Aga Khan University, Karachi, Pakistan

Int Arch Otorhinolaryngol 2020;24:e221–e226.

Address for correspondence Dr. Hamdan Pasha, MBBS, Department of Surgery, Section of Otolaryngology/Head and Neck Surgery, Aga Khan University, National Stadium Road, Karachi, Karachi City, Sindh 74800, Pakistan (e-mail: pasha.hamdan@gmail.com).

Abstract

Introduction Atypia of undetermined significance (AUS) or follicular lesion of undetermined significance (FLUS) is one of the six diagnostic categories of the Bethesda System for Reporting Thyroid Cytopathology. The prevalence of malignancy among Bethesda category III cytology is variable, ranging from 5% to 37% in the literature.

Objective To determine the rate of malignancy in thyroid nodules reported as Bethesda category III.

Methods A total of 495 patients underwent surgical intervention for thyroid nodules from January 2015 to December 2017. The present study included 81 cases reported as Bethesda category III, and their medical records were reviewed.

Results Out of 495 fine-needle aspiration cytology samples, 81 (16.4%) samples were labeled as AUS/FLUS. Among these 81 patients, the mean age was 43.0 years (± 13.9), with only 11 (14%) patients older than 55 years of age. Most of our patients were female (n = 69; 85.2%), and the rest were male. The rate of malignancy based on the final histology was of 33.3% (n = 27). The majority were 17 cases (21%) of papillary carcinoma, followed by follicular carcinoma (n = 6) (7.4%).

Conclusion The risk of malignancy can be higher than it is commonly believed, and guidelines should be based on the data from the institutions themselves for a better assessment of the outcomes.

Keywords
- atypia of undetermined significance
- thyroid nodule
- bethesda
- fine-needle aspiration

Introduction

The global incidence of thyroid cancer is rapidly increasing largely due to incidental thyroid nodules being found on ultrasonography. Nodules have been reported in 50% of patients aged 50 years, with a low overall malignancy risk of 5% to 7%.1,2 The most commonly employed preoperative diagnostic tool is fine-needle aspiration cytology (FNAC) for cancer risk stratification.1–3 It is not only a reliable screening test, but also a reliable and cost-effective method for the differential diagnosis of a thyroid nodule, and it reduces the rate of unnecessary thyroidectomies.1

The Bethesda System for Reporting Thyroid Cytopathology (BSRTC) was introduced in 2007, and it consists of 6 tiered categories (► Table 1) to enhance and standardize the practice of thyroid cytopathology, and subsequently facilitate the better management of thyroid nodules. This has enabled a standardized system for the reporting and management of thyroid gland FNAC results.4 Each category has an implied cancer risk and subsequent recommended management guidelines.

Among its six categories, category III, or atypia of undetermined significance/follicular lesion of undetermined significance (AUS/FLUS) was introduced for cytological features that are neither definitively benign nor definitively neoplastic, and, as such, was meant to encompass a small number of lesions that were difficult to classify. This category, however, remains under heated debate due to variations in outcomes observed across multiple studies. It now includes cases with non-specific categories (► Table 1) to enhance and standardize the practice of thyroid cytopathology, and subsequently facilitate the better management of thyroid nodules. This has enabled a standardized system for the reporting and management of thyroid gland FNAC results.4 Each category has an implied cancer risk and subsequent recommended management guidelines.

Among its six categories, category III, or atypia of undetermined significance/follicular lesion of undetermined significance (AUS/FLUS) was introduced for cytological features that are neither definitively benign nor definitively neoplastic, and, as such, was meant to encompass a small number of lesions that were difficult to classify. This category, however, remains under heated debate due to variations in outcomes observed across multiple studies. It now includes cases with non-specific
patterns affected by compromising factors such as air-drying artifacts, low cellularity or obscuring elements.\textsuperscript{5,6} Currently, the reported risk of malignancy of AUS/FLUS is between 5% and 15%, but recent studies have considered a reevaluation of this probability range.\textsuperscript{7} Some have reported the potential feasibility of using thyroid ultrasound to improve predictions of malignancy of nodules assigned as undetermined cytology in the initial FNAC.\textsuperscript{8–11} A few studies reported very high malignancy rates of up to 48%, suggesting diagnostic lobectomy for all cases of AUS/FLUS nodules.\textsuperscript{12} Others have gone on to suggest further dividing AUS/FLUS into a two-tiered subclassification consisting of low cellularity with predominant microfollicular architecture and absence of colloid, and nuclear atypia (non-benign characteristics) attributable to the strict probability of cancer probability evaluation.\textsuperscript{13–15} Moreover, genetic studies have played their role in predicting cancer risks in such nodules, making some authors suggest their routine use.\textsuperscript{16}

Our study focuses on the diagnostic distribution of Bethesda-III nodules in our institution, and we analyzed the outcomes of AUS/FLUS cases comparing them with reports in the literature. The aim of the study was to determine the rate of malignancy in thyroid nodules reported as Bethesda category III.

**Materials and Methods**

The present study was reviewed and approved by the ethical review committee of a tertiary healthcare center. Due to the observational design of the study, consent from patients was not needed. The data was obtained from the retrospective review of patient medical records from January 2015 to December 2017. The data collected included: patient age and gender, FNAC result, surgical intervention performed, and final histopathology diagnosis.

A total of 495 patients underwent surgical intervention for thyroid nodule, and 81 patients who had AUS/FLUS on the FNAC were recruited for inclusion in the study. Patients whose FNAC results were other than AUS/FLUS, those who had history of any prior surgical intervention for the thyroid, and those who did not undergo surgical intervention were excluded.

The data analysis was performed using the Statistical Package for the Social Sciences (SPSS, IBM Corp., Armonk, NY, US) software, version 23. The FNAC result was compared with the final histopathology report in patients who had AUS/FLUS on the initial cytology, and the frequency of benign nodules and malignancies was observed to calculate the risk.

**Results**

Over the period of two years, preoperative FNAC was performed in 495 patients who underwent thyroid surgery. Out of these 495 FNAC samples, 81 (16.4%) were labeled as having AUS/FLUS (\textsuperscript{–Table 1}).

Amongst these 81 patients, the mean age was 43.0 years (± 13.9), with only 11 (14%) patients older than 55 years of age. Most patients were female (n = 69; 85.2%), and the rest were male. A total of 39 (48.1%) patients underwent total thyroidectomy, whereas the remaining 42 (51.9%) underwent thyroid lobectomy. Intraoperative frozen sections (FFIs) of the lobectomy specimens were not collected from any of the patients. On the final histopathology, 27 (33.3%) cases turned out to be malignant, and most (n = 17 [21%]) were of papillary carcinoma, followed by follicular carcinoma (n = 6 [7.4%]) (\textsuperscript{–Fig. 1}). There were 11 cases of classic variants of papillary carcinoma, 3 of microcarcinomas and 3 of follicular variants of papillary carcinoma.

Out of these 27 malignant cases, 8 patients initially underwent lobectomy and subsequently underwent completion thyroidectomy. Only two of them had papillary carcinoma on the contralateral lobe as well.

**Discussion**

Since the introduction of the BRSRTC, the Bethesda-III category has been increasingly used to classify many undetermined nodules.\textsuperscript{17} The initial risk of malignancy suggested by the BRSRTC ranged from 5% to 15%. However, many later studies reported higher percentages of malignancies in the excised thyroid specimens. The actual incidence of malignancy for this Bethesda category is difficult to determine because many cases undergo repeat FNACs or observation with no histological confirmation of the diagnosis. These debates result in varied management options, ranging from serial ultrasounds and repeat aspirations to thyroidectomies. Many clinicians use ultrasonographic aid with Bethesda classification to determine the risk of malignancy.\textsuperscript{18} Stratifications like the thyroid imaging reporting and data system (TI-RADS) are used to suggest surgical intervention for Bethesda-III nodules when there are suspicious ultrasonographic findings and serial ultrasounds for those without.\textsuperscript{19}

There is varied risk of malignancy reported in the Bethesda-III category: it ranges from 12% to 69% in the resected specimens.\textsuperscript{20–23} This wide variation could be partly explained due to interobserver variability both at the time of obtaining the specimen and during the cytological interpretation. Moreover, the prevalence of malignancy in the population could influence the percentages of malignancy in the resected specimens. However, eliminating the AUS/FLUS category decreases the

<table>
<thead>
<tr>
<th>Bethesda Category</th>
<th>N</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nondiagnostic/Unsatisfactory (I)</td>
<td>44</td>
<td>8.9</td>
</tr>
<tr>
<td>Benign (II)</td>
<td>275</td>
<td>55.6</td>
</tr>
<tr>
<td>AUS/FLUS (III)</td>
<td>81</td>
<td>16.4</td>
</tr>
<tr>
<td>FN/FSN (IV)</td>
<td>32</td>
<td>6.5</td>
</tr>
<tr>
<td>Suspicious for malignancy (V)</td>
<td>46</td>
<td>9.3</td>
</tr>
<tr>
<td>Malignant (VI)</td>
<td>15</td>
<td>3.0</td>
</tr>
<tr>
<td>Total</td>
<td>495</td>
<td>100</td>
</tr>
</tbody>
</table>

Abbreviations: AUS, atypia of undetermined significance; FLUS, follicular lesion of undetermined significance; FN, follicular neoplasm; SFN, suspicious for follicular neoplasm.
FNAC sensitivity and increases the rates of false negative and false positive results. Therefore, it has been suggested that institution-specific and local data should guide the subsequent management of indeterminate nodules.

About 7% of all FNAC results should be interpreted as AUS/FLUS, but this rate has varied between 0.8% and 27%. At our center, nearly 17% of all FNACs were reported as Bethesda III. This rate might be because of the lower frequency of definitive FNAC results like categories V and VI. The overall malignancy risk was found to be higher than what has been previously suggested. One third of all AUS/FLUS nodules harbored malignancy. This can be possibly due to selection bias in a tertiary referral center like ours. None of the nodules were subjected to a repeat FNAC in our cohort to avoid any confounding results. At present, other possible investigative tools like molecular testing are not available at our center.

In our series, 27 out of 81 (33.3%) specimens were found to be malignant. The most common malignancy was papillary carcinoma, which was found in 17 patients. Among these, 11(13.6%) had a classic variant of papillary carcinoma. The follicular variant and microcarcinomas are difficult to be diagnosed using only the FNAC. Three cases of each of these were diagnosed in our cohort on final histology. There were 6 cases of follicular carcinoma, and 4 patients were diagnosed with rare tumors, namely insular carcinoma, anaplastic carcinoma, mucoepidermoid carcinoma and well-differentiated thyroid tumor of uncertain malignant potential.

The most common false positive results were of benign follicular adenomas, followed by thyroiditis and cysts.

We must highlight that we only reviewed cases submitted to surgical intervention. The decision to perform surgery could have been due to the clinical symptoms or worrisome radiologic findings. This would yield a malignancy risk closer to the upper bound estimate which might be a slight overestimation of the actual risk. However, according to the BSRTC, surgical interventions are adequate beyond a risk of 15% and in our setting even the lower bound estimates might still be significant for malignancy. The high malignancy rate in our practice supports the performance of thyroidectomy in patients with AUS. However, there were 22 cases submitted to total thyroidectomy based on the FNAC, but that were later found to have benign pathologies. These could have been adequately addressed with a lobectomy.

Since its advent, FNAC became a routine practice for thyroid nodule assessment, and the role of intraoperative FSs has been debated. Few authors advocate the use of FSs because of the very low false positive rates and the high specificity, of up to 90%. However, several recent series report very low sensitivities, ranging from 22% to 51%. In a recent review, Najah and Tresallet concluded that FSs contributed little to the diagnosis of undetermined thyroid nodules due to their low sensitivity and high false negative rates. They suggested that tumor capsular invasion, which is the hallmark to diagnose malignancy, could not be evaluated on FSs, and was only possible on permanent sections. In fact, FSs jeopardize the detection of capsular invasion because of the fragmentation of the specimen during the process. At our institution, FSs were never performed to augment the diagnosis of cases of Bethesda III on FNAC.

Papillary carcinoma followed by follicular carcinoma were also the two most common histological outcomes for cases of Bethesda III by other authors. In a recent meta-analysis, significant heterogeneity was found among studies with an overall malignancy rate of 27% for AUS/FLUS on FNAC. The cases classified as AUS/FLUS on FNAC had a malignancy rate much higher than that reported according to the BSRTC guidelines, whereas the follicular nodules or suspicion of follicular nodules on FNAC had a malignancy rate that was in line with the BSRTC recommendations. Cibas and Ali revised the usual management of the AUS/FLUS category through repeat FNAC.
molecular testing, or lobectomy, and implied that the risk of malignancy was between 10% and 30% based on a meta-analysis of the literature published after 2007.  

The analysis of the correlation of cytological and histological data can aid institutions and individuals enhance the criteria for diagnosis and subsequent management. However, it is important to perform the cytological-histological correlation with the understanding that the data are an overestimation of the risk of malignancy for cases of AUS/FLUS. In our setting, lobectomy seemed to be an adequate intervention for a diagnosis of AUS/FLUS.

**Conclusion**

We conclude that malignancy risks can be higher in some settings compared with customary beliefs. We recommend a Bethesda-III FNAC result warrants a lobectomy for definitive histological diagnosis. However, a total thyroidectomy should not be performed based on isolated reports of Bethesda III on the cytology.

**Presentation**

The abstract was presented at 10th International Academic Conference in Otology, Rhinology and Laryngology (ORLJAC 2018), which was held from March 1st to 3rd, 2018 at Makati, the Philippines.

**Conflict of Interests**

The authors have none to disclose.

**References**

3. Cross PA, Poller D. The Bethesda thyroid terminology and progress towards an international agreement on thyroid FNA cytology reporting. Cytopathology 2010;21(02):71–74
17. Sullivan PS, Hirschowitz SL, Fung PC, Apple SK. The impact of atypia/ follicular lesion of undetermined significance and repeat fine-needle aspiration: 5 years before and after implementation of the Bethesda System. Cancer Cytopathol 2014;122(12):866–872
19. Maia FFR, Matos PS, Pavin EJ, Zantut-Wittmann DE. Thyroid imaging reporting and data system score combined with Bethesda system for malignancy risk stratification in thyroid nodules with indeterminate results on cytology. Clin Endocrinol (Oxf) 2015;82(03):439–444
22. Harvey AM, Mody DR, Amricki M. Thyroid fine-needle aspiration reporting rates and outcomes before and after Bethesda implementation within a combined academic and community hospital system. Arch Pathol Lab Med 2013;137(11):1664–1668
25. Broome JT, Solorzano CC. The impact of atypia/follicular lesion of undetermined significance on the rate of malignancy in thyroid fine-
needle aspiration: evaluation of the Bethesda System for Reporting Thyroid Cytopathology. Surgery 2011;150(06):1234–1241


37 Cibas ES, Ali SZ. The 2017 Bethesda System for Reporting Thyroid Cytopathology. Thyroid 2017;27(11):1341–1346